Rockefeller Capital Management’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Rockefeller Capital Management’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.3K	Sell	1,056 -59	-5%	-$3K	﹤0.01%	3224
2025 Q4	$57.1K	Buy	1,115 +20	+2%	+$925	﹤0.01%	3010
2025 Q3	$42.6K	Buy	+1,095	New	+$37.6K	﹤0.01%	2990
2023 Q1	–	Sell	-52	Closed	-$1K	–	3552
2022 Q4	$1K	Hold	52	–	–	﹤0.01%	3747
2022 Q3	$1K	Buy	52 +2	+4%	+$63	﹤0.01%	3778
2022 Q2	$1K	Hold	50	–	–	﹤0.01%	4007
2022 Q1	$1K	Hold	50	–	–	﹤0.01%	3772
2021 Q4	$2K	Hold	50	–	–	﹤0.01%	3565
2021 Q3	$2K	Buy	+50	New	+$2.29K	﹤0.01%	3477
2021 Q2	–	Sell	-4,000	Closed	-$201K	–	3580
2021 Q1	$201K	Hold	4,000	–	–	﹤0.01%	1330
2020 Q4	$204K	Hold	4,000	–	–	﹤0.01%	1186
2020 Q3	$164K	Hold	4,000	–	–	﹤0.01%	1106
2020 Q2	$167K	Hold	4,000	–	–	﹤0.01%	1007
2020 Q1	$127K	Buy	+4,000	New	+$153K	﹤0.01%	946

Other funds holding SBIO

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIS

Connors Investor Services Wyomissing, Pennsylvania $1.08B AUM 31.31% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.27B AUM 25.8% 1-Year Est. Return

Rockefeller Capital Management's SBIO Position: Q1 2026 in Review

Rockefeller Capital Management reduced its ALPS Medical Breakthroughs ETF (SBIO) stake by 5.3% in Q1 2026, selling an estimated $3K and leaving 1,056 shares worth $55.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3224.

Rockefeller Capital Management first reported a position in SBIO in Q1 2020 and has held it in 14 quarters since. The position peaked at $204K in Q4 2020. 59 funds tracked by Wall St. Rank hold SBIO as of Q1 2026.

Rockefeller Capital Management held 1,056 shares of ALPS Medical Breakthroughs ETF worth $55.3K as of Q1 2026.
Rockefeller Capital Management sold 59 ALPS Medical Breakthroughs ETF shares in Q1 2026, an estimated $3K.
ALPS Medical Breakthroughs ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3224 holding.
Rockefeller Capital Management first reported a position in ALPS Medical Breakthroughs ETF in Q1 2020 and has held it in 14 quarters since.
Rockefeller Capital Management's ALPS Medical Breakthroughs ETF position peaked at $204K in Q4 2020.
59 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.